MDB Capital Upgrades Maxygen (MAXY) to Buy

January 7, 2008 8:17 AM EST
Get Alerts MAXY Hot Sheet
Price: $2.53 --0%

Rating Summary:
    0 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 4 | New: 24
Trade Now! 
Join SI Premium – FREE
MDB Capital upgrades and reinstates its coverage on Maxygen (Nasdaq: MAXY) with a Buy rating and a $15 price target.

The firm said it is optimistic about the potential of MAXY-G34 and Maxygen's protein optimization pipeline and technology platform. Furthermore, MDB said that the Street is currently undervaluing Maxygen's stake in Codexis.

Maxygen, Inc., a biotechnology company, engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions.

You May Also Be Interested In

Related Categories